LISA PETERSON: Open Payments
NPI 1073682993 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,017 in 56 payments from 19 companies in 2025. Trend: 2023 $1,029 · 2024 $718 · 2025 $1,017
Food & beverage: $1,017
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $200 |
| Astellas Pharma US Inc | 5 | $153 |
| Amgen Inc. | 12 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| ABBVIE INC. | 3 | $54 |
| Abbott Laboratories | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
Products named: Veozah, Wegovy, EVENITY, CAPLYTA, OTEZLA, Ozempic, FREESTYLE LIBRE 3, OPSUMIT.
Industry payments across NE — which companies pay providers there.
